Patents by Inventor Laurence J. Neil Cooper

Laurence J. Neil Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Car+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
    Patent number: 11344577
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf” treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: May 31, 2022
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J. Neil Cooper, Hiroki Torikai
  • CAR+ T CELLS GENETICALLY MODIFIED TO ELIMINATE EXPRESSION OF T-CELL RECEPTOR AND/OR HLA
    Publication number: 20190388472
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf” treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Application
    Filed: July 8, 2019
    Publication date: December 26, 2019
    Inventors: Laurence J. Neil COOPER, Hiroki TORIKAI
  • CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
    Patent number: 10391126
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: August 27, 2019
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Laurence J. Neil Cooper, Hiroki Torikai
  • CAR+ T CELLS GENETICALLY MODIFIED TO ELIMINATE EXPRESSION OF T-CELL RECEPTOR AND/OR HLA
    Publication number: 20140349402
    Abstract: The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.
    Type: Application
    Filed: November 16, 2012
    Publication date: November 27, 2014
    Applicant: Board of Regents, The University of Texas System
    Inventors: Laurence J. Neil Cooper, Hiroki Torikai